NCT02207504 - Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 2, 2018

Study Completion Date

January 3, 2022

Conditions

Castration-resistant Prostate Cancer

Interventions

DRUG

Crizotinib

Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.

DRUG

Enzalutamide

Enzalutamide is an androgen receptor signaling inhibitor.

Trial Locations (1)

Dana Farber Cancer Institute, Boston